> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period Determined for Aklief
- URL: https://www.fdaweb.com/regulatory-review-period-determined-for-aklief/
- Published: 2021-11-03T12:00:00.000Z
- Updated: 2026-09-14T17:21:18.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5150505

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for Galderma’s Aklief (trifarotene), indicated for topical treatment of acne vulgaris in patients nine years of age and older. The review period is 3,137 days, which includes 2,771 days that occurred during the testing phase and 366 days during the approval phase. To view the notice, click [here](https://public-inspection.federalregister.gov/2021-24077.pdf?ref=fdaweb.com).